DeutschNewstral
Article
jdsupra.com on 2018-06-15 19:44
FDA guidances promote greater communication to payors about medical product value, clarify CFL communications
Related news
- FDA and Life Sciences FDA Finalizes Guidances for “Consistent Communications” and Payor Communicationsjdsupra.com
- FDA Guidance on HCEI and Communications to Payors of Unapproved Products and Usesjdsupra.com
- FDA Allows Off-label Communications to Payors, Formulary Committees, and Similar Entities. What’s Next?jdsupra.com
- FDA Issues Guidance on Drug and Device Manufacturer Communications: Part I – Health Care Economic Information and Unapproved Products/Use Communications with Payorsjdsupra.com
- New FDA Biosimilar Guidances and Proposed Rulejdsupra.com
- FDA Releases Two Guidances for Innovative Drug Developmentjdsupra.com
- FDA Releases Two Draft Guidances on REMSjdsupra.com
- USPTO Issues Revised Guidances Concerning 35 U.S.C. §§ 101 and 112jdsupra.com
- Guidances galore: FDA finalizes multiple digital health guidance documentsjdsupra.com
- FDA finalizes two guidances clarifying DSCSA enforcement exemptions and issues product identifier Q&Ajdsupra.com
- Four new FDA guidances and proposed rule advance biosimilars policy frameworkjdsupra.com
- Commercial Payors and Medicaid Telehealth Billingjdsupra.com
- FDA Updates Digital Health Guidances to Align with 21st Century Cures Actjdsupra.com
- FDA’s Draft Guidances on Medical Device Inspection Transparency: Anything New Here?jdsupra.com
- California Legislature Mulls Rewrite Of "Broker" Definition In CFLjdsupra.com
- DBO Reports Record Number Of CFL Licenseesjdsupra.com
- Honest Communication is Neededjdsupra.com
- HHS Proposes Rule Challenging Drug Manufacturer Rebates to PBMs and Payorsjdsupra.com
- FDA Issues Two Product-Specific Guidances for Chloroquine Phosphate and Hydroxychloroquine Sulfate Drug Developersjdsupra.com
- Anticipated Proposed Regulations Clarify Hardship Distribution Rulesjdsupra.com